Australian government earmarks A$630 million for over 800 innovative research projects

9 November 2015

Australia’s Turnbull government will invest more than A$630 million ($443.7 million) to support Australia’s world-leading researchers to find the next prevention of disease or cure as it continues to drive innovation in Australia, Minister for Health Sussan Ley announced today.

Ms Ley said that over 2,000 researchers would share in the A$630 million for projects including: obesity prevention; cancer genomics and hereditary diseases; a new medication to help treat severe ice addiction; new treatment for drug-resistant depression; different treatments for post-traumatic stress disorder (PTSD) and the impact shift working has on pregnancy outcomes.

Ms Ley said the announcement includes A$122 million for cancer research, A$50 million for mental health research and A$25 million for dementia research, amongst other diseases and conditions. The funding will support 836 projects and the work of approximately 2200 researchers.

She said the establishment of the Medical Research Future Fund had sent a clear message that the Turnbull government is “absolutely committed” to supporting health and medical research in Australia well into the future. “The landmark Medical Research Future Fund will identify and coordinate national health priorities, as well as continue to support individual research projects through the National Health and Medical Research Council,” Ms Ley said.

National Health and Medical Research Council chief executive Anne Kelso said the announcement also included the second largest grant in NHMRC history, worth A$25 million over five years. “Drawing together a national network of more than 80 team members, this potentially transformative project will examine how to use the extraordinary recent advances in human genetics to improve patient care in Australia,” Prof Kelso said.

The grants were selected by independent panels which drew on the expertise of thousands of researchers to assess applications across 12 different NHMRC schemes.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical